FT Options’s Global Blood Therapeutics, Inc. GBT Stock Holding History

FT Options’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20,000	Closed	-$54K	–	278
2017 Q2	$54K	Buy	+20,000	New	+$595K	0.09%	107

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FT Options's GBT Position: Q3 2017 in Review

FT Options sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2017, closing a stake of 1,805 shares — an estimated $49K sold.

FT Options first reported a position in GBT in Q1 2016 and held it in 2 quarters. The position peaked at $424K in Q1 2016. 136 funds tracked by Wall St. Rank hold GBT as of Q3 2017.

FT Options reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
FT Options sold 1,805 Global Blood Therapeutics, Inc. shares in Q3 2017, an estimated $49K.
FT Options first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
FT Options's Global Blood Therapeutics, Inc. position peaked at $424K in Q1 2016.
136 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.